局所進行性または転移性固形腫瘍(六価OX40アゴニスト)を有する被験者におけるペムブロリズマブと組み合わせたINBRX-106およびINBRX-106の研究
局所進行性または転移性固形腫瘍の被験者を対象としたペムブロリズマブと組み合わせた INBRX-106 および INBRX-106 の非盲検、多施設共同、ヒト初、用量漸増、第 1 相試験
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Study Director - Inhibrx Biosciences, Inc
- 電話番号:858-500-7833
- メール:clinicaltrials@inhibrx.com
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 積極的、募集していない
- City of Hope
-
Glendale、California、アメリカ、91204
- 募集
- Oncura Health
-
コンタクト:
- Elizabeth Brown
- メール:Elizabeth.Brown@lahomg.com
-
主任研究者:
- Sungwon Kyung, MD
-
La Jolla、California、アメリカ、92037
- まだ募集していません
- UC San Diego Health - Moores Cancer Center
-
主任研究者:
- Lyudmila Bazhenova, MD
-
Los Angeles、California、アメリカ、90027
- 募集
- California Research Institute
-
主任研究者:
- Ghassan Al-Jazayrly, MD
-
コンタクト:
- Swati Shrestha
- メール:sw@caresinst.com
-
Los Angeles、California、アメリカ、90069
- 募集
- Valkyrie Clinical Trials
-
主任研究者:
- David Berz, MD
-
コンタクト:
- Myo Zaw
- メール:myo.zaw@valkyrieclinicaltrials.com
-
Los Angeles、California、アメリカ、90033
- まだ募集していません
- University of Southern California Norris Comprehensive Cancer Center
-
主任研究者:
- Jorge Nieva, MD
-
Murrieta、California、アメリカ、92562
- 募集
- Valkyrie Clinical Trials
-
主任研究者:
- David Berz, MD
-
コンタクト:
- Isabella Gudino
- メール:Isabella.gudino@vctcare.com
-
Santa Rosa、California、アメリカ、95403
- 募集
- Providence Medical Foundation
-
主任研究者:
- Ian Anderson, MD
-
コンタクト:
- Clinical Research Coordinator
- 電話番号:1181 707-521-3810
- メール:jackson.barnard@providence.org
-
-
Colorado
-
Lakewood、Colorado、アメリカ、80228
- まだ募集していません
- Valkyrie Clinical Trials - Colorado
-
主任研究者:
- Jason Henry, MD
-
-
Florida
-
Clermont、Florida、アメリカ、34711
- 募集
- Clermont Oncology Center
-
主任研究者:
- Gopal Kunta, MD
-
コンタクト:
- Kiran Penta
- メール:kiran@aorcorp.com
-
Orange City、Florida、アメリカ、32763
- 募集
- Mid Florida Hematology and Oncology Center
-
主任研究者:
- Santosh Nair, MD
-
コンタクト:
- Kiran Penta
- メール:kiran@aorcorp.com
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 積極的、募集していない
- Winship Cancer Institute - Emory University
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- まだ募集していません
- University of Illinois Cancer Center
-
主任研究者:
- Frank Weinberg, MD, PhD
-
Chicago、Illinois、アメリカ、60637
- 積極的、募集していない
- The University of Chicago Medical Center
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- 募集
- University of Iowa
-
主任研究者:
- Douglas Laux, MD
-
コンタクト:
- Jordan Harrelson
- 電話番号:319-467-5831
- メール:Jordan-harrelson@uiowa.edu
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- 募集
- Norton Cancer Institute
-
主任研究者:
- John Hamm, MD
-
コンタクト:
- Jenn Broadway, RN
- 電話番号:19535 502-629-2500
- メール:Jennifer.Broadway@nortonhealthcare.org
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- 募集
- Henry Ford Cancer Institute
-
主任研究者:
- Amy Weise, MD
-
コンタクト:
- Mahmoud Hossami
- 電話番号:313-725-7842
- メール:mhossam1@hfhs.org
-
Detroit、Michigan、アメリカ、48201
- 完了
- Barbara Ann Karmanos Cancer Institute
-
Grand Rapids、Michigan、アメリカ、49546
- 積極的、募集していない
- START Midwest
-
-
Minnesota
-
Saint Louis Park、Minnesota、アメリカ、55426
- 積極的、募集していない
- HealthPartners Cancer Research Center
-
Saint Paul、Minnesota、アメリカ、55101
- 完了
- HealthPartners Cancer Research Center (Regions Hospital)
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- まだ募集していません
- Washington University in St. Louis School of Medicine
-
主任研究者:
- Brett Herzog, MD, PhD
-
-
Montana
-
Billings、Montana、アメリカ、59102
- 完了
- Intermountain Health Cancer Centers of Montana
-
-
Nebraska
-
Grand Island、Nebraska、アメリカ、68803
- まだ募集していません
- Nebraska Cancer Specialists - Grand Island
-
主任研究者:
- Ralph Hauke, MD
-
Omaha、Nebraska、アメリカ、68130
- 募集
- Nebraska Cancer Specialists
-
主任研究者:
- Ralph Hauke, MD
-
コンタクト:
- Lindsey Becker
- 電話番号:402-691-5255
- メール:lbecker@nebraskacancer.com
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- まだ募集していません
- MD Anderson Cancer Center at Cooper
-
主任研究者:
- Polina Khrizman, MD
-
-
New York
-
The Bronx、New York、アメリカ、10467
- 積極的、募集していない
- Montefiore Medical Center
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- 積極的、募集していない
- Cleveland Clinic
-
-
Oregon
-
Portland、Oregon、アメリカ、97213
- 積極的、募集していない
- Providence Portland Medical Center
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- まだ募集していません
- Lehigh Valley Health Network
-
主任研究者:
- Muhammad Rizvi, MD
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37923
- まだ募集していません
- University of Tennessee Health Science Center
-
主任研究者:
- Sean Jordan, MD
-
Nashville、Tennessee、アメリカ、37204
- 積極的、募集していない
- Vanderbilt University School of Medicine
-
-
Texas
-
Dallas、Texas、アメリカ、75230
- 完了
- Sarah Cannon Research Institute at Mary Crowley
-
El Paso、Texas、アメリカ、79915
- 完了
- Renovatio Clinical - El Paso
-
San Antonio、Texas、アメリカ、78229
- 完了
- NEXT Oncology
-
The Woodlands、Texas、アメリカ、77380
- 完了
- Renovatio Clinical
-
Tyler、Texas、アメリカ、75701
- 募集
- The University of Texas Health Science Center at Tyler
-
コンタクト:
- Chaney Story
- メール:Chaney.Story@uttyler.edu
-
主任研究者:
- Erminia Massarelli, MD, PhD, MS
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 完了
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- 募集
- Froedtert Hospital and the Medical College of Wisconsin
-
主任研究者:
- Jonathan Thompson, MD
-
コンタクト:
- Ellen Smith
- メール:eksmith@mcw.edu
-
-
-
-
-
Singapore、シンガポール
- 完了
- Curie Oncology
-
Singapore、シンガポール
- 完了
- Icon Cancer Centre Farrer Park
-
Singapore、シンガポール
- 完了
- Icon Cancer Centre Mount Alvernia
-
-
-
-
-
Changhua、台湾
- 積極的、募集していない
- Changhua Christian Hospital (CCH)
-
Kaohsiung City、台湾
- 積極的、募集していない
- E-Da Cancer Hospital
-
Kaohsiung City、台湾
- 積極的、募集していない
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Tainan、台湾
- 積極的、募集していない
- National Cheng Kung University Hospital
-
Taipei、台湾
- 完了
- Taipei Veterans General Hospital
-
-
-
-
-
Busan、韓国
- まだ募集していません
- Inje University College of Medicine
-
主任研究者:
- IL-Hwan Kim, MD, PhD
-
Cheongju-si、韓国
- まだ募集していません
- Chungbuk National University Hospital
-
主任研究者:
- Ki-Hyeong Lee, MD
-
Gyeonggi-do、韓国
- 募集
- The Catholic University of Korea, St. Vincent's Hospital
-
主任研究者:
- Byoung Yong Shim
-
Hwasun、韓国
- まだ募集していません
- Chonnam National University Hwasun Hospital
-
主任研究者:
- In-Jae Oh, MD, MS, PhD
-
Incheon、韓国
- まだ募集していません
- Gachon University Gil Medical Center
-
主任研究者:
- Eun Kyung Cho, PhD, M.S
-
Seongnam-si、韓国
- まだ募集していません
- CHA Bundang Medical Center
-
主任研究者:
- Yoon Beom Sang
-
Seoul、韓国
- 募集
- Asan Medical Center
-
コンタクト:
- Bokyeong Jung, RN
- メール:bokyeong_jung@amc.seoul.kr
-
主任研究者:
- Dae Ho Lee, MD
-
Seoul、韓国
- 募集
- Severance Hospital, Yonsei University Health System
-
コンタクト:
- Miyeon Lee
- メール:lee_my@yuhs.ac
-
主任研究者:
- Sun Mun Lim
-
Seoul、韓国
- 募集
- The Catholic University of Korea Seoul St. Mary's Hospital,
-
主任研究者:
- SookHee Hong
-
コンタクト:
- Na Ayn
- メール:Ahnna331@gmail.com
-
Seoul、韓国
- まだ募集していません
- Korea University Anam Hospital
-
主任研究者:
- Yoon Ji Choi, MD, MS, PhD
-
Seoul、韓国
- まだ募集していません
- Hanyang University Seoul Hospital
-
主任研究者:
- Myung- Ju Ahn, MD, PhD, MS
-
Seoul、韓国
- まだ募集していません
- Korea University Guro Hospital
-
主任研究者:
- Sung Yong Lee
-
主任研究者:
- Sung Yong Lee, MD, MS, PhD
-
Suwon、韓国
- まだ募集していません
- Ajou University Hospital
-
主任研究者:
- Yong-Won Choi, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Select Inclusion Criteria:
- Males or females aged ≥18 years.
- Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
- Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
- Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
- For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
- For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
- For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
- All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
- PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
- Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.
Select Exclusion Criteria:
- Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
- Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
- Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- Additional in- and exclusion criteria per protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1 INBRX-106 Escalation (Not Recruiting)
INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
実験的:Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)
INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
|
|
実験的:Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
|
|
実験的:Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)
Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
|
|
実験的:Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
他の名前:
|
|
実験的:Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
他の名前:
|
|
アクティブコンパレータ:Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
実験的:Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
実験的:Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
|
|
実験的:Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting
Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
|
|
実験的:Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)
Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
他の名前:
|
|
実験的:Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
他の名前:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 |
|
実験的:Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4 |
|
実験的:Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
|
|
実験的:Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC
Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
他の名前:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
他の名前:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
時間枠:~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
時間枠:~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
時間枠:~2 years
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab |
~2 years
|
|
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
時間枠:~2 years
|
The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1 |
~2 years
|
|
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
時間枠:~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
時間枠:~2 years
|
Major pathological response (mPR) and pathological complete response (cPR) criteria. |
~2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area under the serum concentration time curve (AUC) of INBRX-106
時間枠:~2 years
|
Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Maximum observed serum concentration (Cmax) of INBRX-106
時間枠:~2 years
|
Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Trough observed serum concentration (Ctrough) of INBRX-106
時間枠:~2 years
|
Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Time to Cmax (Tmax) of INBRX-106
時間枠:~2 years
|
Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Immunogenicity of INBRX-106
時間枠:~2 years
|
Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
時間枠:~2 years
|
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
~2 years
|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
時間枠:~2 years
|
Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
~2 years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Lead、Inhibrx Biosciences, Inc
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 口の病気
- 顎口腔疾患
- 泌尿生殖器腫瘍
- 男性の泌尿生殖器疾患
- 腎臓病
- 泌尿器疾患
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 気道疾患
- 消化器腫瘍
- 消化器系腫瘍
- 消化器系疾患
- 消化器疾患
- 胃の病気
- 肺疾患
- 腺癌
- 気道腫瘍
- 胸部腫瘍
- 皮膚疾患
- 泌尿器科の新生物
- 耳鼻咽喉科疾患
- 神経外胚葉性腫瘍
- 新生物、生殖細胞および胚
- 新生物、神経組織
- 腎腫瘍
- がん、気管支原性
- 気管支腫瘍
- 神経内分泌腫瘍
- 咽頭腫瘍
- 耳鼻咽喉科の新生物
- 咽頭疾患
- 母斑とメラノーマ
- 皮膚腫瘍
- 皮膚および結合組織疾患
- 頭頸部の扁平上皮がん
- 新生物
- 胃の新生物
- がん
- 肺新生物
- がん、扁平上皮細胞
- がん、腎細胞
- がん、非小細胞肺
- 頭頸部腫瘍
- メラノーマ
- 組織型別の新生物
- 新生物、腺および上皮
- 新生物、扁平上皮細胞
- 口の新生物
- がん、移行細胞
- 中咽頭腫瘍
- 部位別新生物
- 下咽頭腫瘍
- アミノ酸、ペプチド、およびタンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- 無機化学物質
- 塩素化合物
- 窒素化合物
- グアニン
- ヒポキサンチン
- ピリノン
- プリン
- グルタミン酸
- アミノ酸、酸性
- アミノ酸
- アミノ酸、ジカルボン酸
- タキソイド
- シクロデカン
- Diterpenes
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- ヘルスケアの経済学と組織
- プラチナ化合物
- 経済
- ペメトレキセド
- ゲムシタビン
- パクリタキセル
- シスプラチン
- ペンブロリズマブ
- 税金
その他の研究ID番号
- Ph 1 Ph 2 INBRX-106
- KEYNOTE A99 and MK-3475-A99 (その他の識別子:Merck Sharp & Dohme LLC)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。